Completed PHASE1 INTERVENTIONAL 2-arm NCT07416955

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

An Open Label, Randomized, Two-treatment, Two Sequence, Two Period, Crossover, Single Dose, Comparative Pharmacokinetic, Immunogenicity and Safety Study of Pegfilgrastim Comparing TPI-120 Pre-Filled Syringe With Auto- Injector 6 mg/0.6 mL (T) and Fylnetra Pre-filled Syringe 6 mg/0.6 mL (R) Administered Through Subcutaneous Route, in Normal, Healthy, Adult Human Subjects Under Fasting Conditions

Sponsor: Cliantha Research

Conditions Healthy Volunteer

Interventions TPI-120 Pre-Filled Syringe 6 mg/0.6 mL

Updated 1 time since 2026 Last updated: Feb 17, 2026 Started: Apr 5, 2025 Primary completion: Oct 10, 2025 Completion: Oct 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteer, this trial is completed. The trial is conducted by Cliantha Research and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

1 version recorded

Completed — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cliantha Research
Kashiv BioSciences, LLC

Data source: Kashiv BioSciences, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St. Petersburg, United States